As Israel’s Teva Pharmaceutical Industries (TEVA) unveiled its $82 per share bid for Mylan (MYL) Tuesday, the hostile takeover attempt may be a harbinger of things to come. As consolidation increases in the generics pharmaceutical area, it may leave very few companies standing as potential targets. Mylan already has an outstanding $29 billion offer for Perrigo (PRGO). Other big consolidators in the sector besides Teva include Actavis (ACT), Forest Laboratories (FRX) and Abbott Laboratories (ABT), The Deal’s Laura Cooper reports. But as the deal field narrows and bigger deals are announced, they are also likely to draw the attention of regulators.
Subscribe to TheStreetTV on YouTube:
For more content from TheStreet visit:
Check out all our videos:
Follow TheStreet on Twitter:
Like TheStreet on Facebook:
Follow TheStreet on LinkedIn:
Follow TheStreet on Google+:
source
